Login
$BNTC
$8.54 -$0.50 (5.53%) Live

$BNTC SEC Filings

Filed On Filing
13 Nov 2026 10-Q
13 Nov 2026 8-K: Results of Operations and Financial Condition; Amendments to Articles/Bylaws; Change in Fiscal Year

Positive interim clinical results from the ongoing BB-301 Phase 1b/2a study for dysphagic patients with Oculopharyngeal Muscular Dystrophy (OPMD), presented as a late-breaking poster at the European Society of Gene and Cell Therapy (ESGC...

28 Oct 2026 8-K: Regulation FD Disclosure

Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301

20 Oct 2026 DEFA14A
20 Oct 2026 Proxy statement: annual meeting on December 3, 2026

CEO pay $6.5M, down 75% · say-on-pay vote

05 Oct 2026 8-K: Regulation FD Disclosure

The BB-301 pivotal trial remains on track to begin in mid-2027

30 Sep 2026 8-K: Changes in Registrant's Certifying Accountant

As previously disclosed on a Current Report on Form 8-K with the Securities and Exchange Commission that Benitec Biopharma Inc. (the “Company”) filed on September 24, 2026, the Company reported the approval of the engagement of Ernst & Y...

24 Sep 2026 8-K: Changes in Registrant's Certifying Accountant

We are the former independent registered public accounting firm for Benitec Biopharma Inc. (the “Company”). We have read the Company’s disclosure set forth in Item 4.01 “Changes in Registrant’s Certifying Accountant” of the Company’s Cur...

21 Sep 2026 EFFECT
14 Sep 2026 S-3
14 Sep 2026 10-K
14 Sep 2026 8-K: Results of Operations and Financial Condition

All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients having been safely treated

30 Jun 2026 Form 4: Buchi J Kevin, Director

Gave 51,813 shares as a gift

29 May 2026 8-K: Departure/Election of Directors or Officers; Compensation

On May 22, 2026, the Board of Directors (the “Board”) of Benitec Biopharma Inc. (the “Company”) appointed David Friedman to serve as a director of the Board, effective as of such date. Mr. Friedman was appointed as a Class III member of ...

28 May 2026 Form 4: Friedman David Matthew, Director

Granted 35,000 Options (right to buy)

28 May 2026 Form 3: Friedman David Matthew, Director

No securities owned

14 May 2026 10-Q
14 May 2026 8-K: Results of Operations and Financial Condition

Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 24-months post-treatment and further i...

03 Apr 2026 UPLOAD
20 Mar 2026 CORRESP

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support